$252M Potential in CLDA and CombinatoRx Deal

Xconomy Boston — 

Cambridge, MA-based drug developer CombinatoRx (NASDAQ:CRXX) has licensed a compound from Clinical Data (NASDAQ:CLDA), of Newton, MA, to develop a combination treatment for multiple myeloma and other B-cell cancers, according to a press release. Clinical Data is eligible for up to $252 million in milestone fees from CombinatoRx and royalty payments on potential drug sales.